Less favorable survival outcomes in BRAF-altered patients of class 2 and 3 have also been reported with chemotherapy, mainly due to the presence of more aggressive clinical features compared to NSCLC patients with class 1 alterations, such as a higher frequency of extra-thoracic dissemination [27]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.